Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors

Luminal Androgen Receptor and Molecular Apocrine Breast Cancers constitute a single molecular entity within estrogen receptor-negative breast cancers. The validated four-gene signature enables robust clinical identification and may guide future therapeutic stratification.

Authors

Adrien Borgel (ORCID: https://orcid.org/0000-0003-0267-2065)
Catherine Miquel
Philippe Bertheau
Luis Teixeira
Jacqueline Lehmann-Che
Etienne Camenen

Institutions

Inserm (FR)
Université Paris Cité (FR)
Sorbonne Paris Cité (FR)
Assistance Publique – Hôpitaux de Paris (FR)
Institut Cochin (FR)
Hôpital Saint-Louis (FR)

Publication Details

Journal: Breast Cancer Research
Published: 2025-12-27
DOI: https://doi.org/10.1186/s13058-025-02187-3
Primary Topic: Breast Cancer Treatment Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors

Adrien Borgel, Catherine Miquel, Philippe Bertheau, Luis Teixeira et al.

Dec 27, 2025

Breast Cancer Research

Breast Cancer Treatment Studies

article

Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors

Adrien Borgel, Catherine Miquel, Philippe Bertheau, Luis Teixeira, Jacqueline Lehmann-Che, Etienne Camenen

December 27, 2025article en

Abstract

Luminal Androgen Receptor and Molecular Apocrine Breast Cancers constitute a single molecular entity within estrogen receptor-negative breast cancers. The validated four-gene signature enables robust clinical identification and may guide future therapeutic stratification.

Breast Cancer ResearchVol. 28(1)

Inserm (FR), Université Paris Cité (FR), Sorbonne Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), Institut Cochin (FR), Hôpital Saint-Louis (FR)

Openalex Percentile: Top 33%

Breast Cancer Treatment Studies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.